歐康維視生物-B(01477.HK)年度收益增加55.0%至2.46億元
格隆匯3月21日丨歐康維視生物-B(01477.HK)公吿,截至2023年12月31日止年度,公司收益增加55.0%至人民幣246.4百萬元,主要得益於銷售眼科產品及醫藥產品推廣服務產生的收益大幅增加。
截至2023年12月31日止年度,公司的虧損為人民幣379.8百萬元,較截至2022年12月31日止年度的人民幣402.6百萬元減少5.7%,主要由於與去年相比,毛利增加人民幣41.4百萬元及研發開支減少人民幣60.5百萬元,與去年相比,部分被其他收入及其他收益合共減少人民幣27.0百萬元以及銷售及營銷開支增加人民幣43.2百萬元所抵銷。
報吿期內,公司錄得研發開支人民幣123.8百萬元,較截至2022年12月31日止年度的人民幣184.3百萬元減少32.8%,主要由於(i)與去年相比,於報吿期內向研發人員支付的以股份為基礎的付款減少;及(ii)第三方承包成本的減少。
截止目前,公司已擁有眼前及眼後段25種藥物資產,建立起了完整的眼科藥物產品線,其中五款產品正處於III期臨牀試驗,涵蓋所有主要的眼睛前部及後部疾病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.